JPH11508905A - アミノ置換ビスホスホン酸 - Google Patents
アミノ置換ビスホスホン酸Info
- Publication number
- JPH11508905A JPH11508905A JP9505494A JP50549497A JPH11508905A JP H11508905 A JPH11508905 A JP H11508905A JP 9505494 A JP9505494 A JP 9505494A JP 50549497 A JP50549497 A JP 50549497A JP H11508905 A JPH11508905 A JP H11508905A
- Authority
- JP
- Japan
- Prior art keywords
- use according
- simultaneous
- bone
- sequential administration
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 239000002253 acid Substances 0.000 title claims abstract description 37
- 125000003277 amino group Chemical group 0.000 title description 6
- 210000000988 bone and bone Anatomy 0.000 claims abstract description 21
- -1 N, N-dimethylamino Chemical group 0.000 claims abstract description 13
- 150000003839 salts Chemical class 0.000 claims abstract description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical class [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000003745 diagnosis Methods 0.000 claims abstract description 6
- 239000013543 active substance Substances 0.000 claims abstract description 5
- 238000002360 preparation method Methods 0.000 claims abstract description 5
- 230000002265 prevention Effects 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims abstract description 4
- 208000018083 Bone metabolism disease Diseases 0.000 claims abstract 2
- 208000027361 mineral metabolism disease Diseases 0.000 claims abstract 2
- 238000000034 method Methods 0.000 claims description 10
- 208000001132 Osteoporosis Diseases 0.000 claims description 4
- 230000002308 calcification Effects 0.000 claims description 4
- 239000000824 cytostatic agent Chemical class 0.000 claims description 4
- 206010007027 Calculus urinary Diseases 0.000 claims description 3
- 206010003246 arthritis Diseases 0.000 claims description 3
- 239000003102 growth factor Substances 0.000 claims description 3
- 229940088597 hormone Drugs 0.000 claims description 3
- 239000005556 hormone Substances 0.000 claims description 3
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims description 3
- 150000003180 prostaglandins Chemical class 0.000 claims description 3
- 208000008281 urolithiasis Diseases 0.000 claims description 3
- 102000004127 Cytokines Human genes 0.000 claims description 2
- 108090000695 Cytokines Proteins 0.000 claims description 2
- 102000003982 Parathyroid hormone Human genes 0.000 claims description 2
- 108090000445 Parathyroid hormone Proteins 0.000 claims description 2
- 229930003316 Vitamin D Natural products 0.000 claims description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 claims description 2
- 239000003098 androgen Substances 0.000 claims description 2
- 159000000007 calcium salts Chemical class 0.000 claims description 2
- 229940011871 estrogen Drugs 0.000 claims description 2
- 239000000262 estrogen Substances 0.000 claims description 2
- 239000000199 parathyroid hormone Substances 0.000 claims description 2
- 229960001319 parathyroid hormone Drugs 0.000 claims description 2
- 208000028169 periodontal disease Diseases 0.000 claims description 2
- 235000019166 vitamin D Nutrition 0.000 claims description 2
- 239000011710 vitamin D Substances 0.000 claims description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 claims description 2
- 229940046008 vitamin d Drugs 0.000 claims description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- 150000001413 amino acids Chemical class 0.000 claims 2
- 239000004471 Glycine Substances 0.000 claims 1
- 150000004347 all-trans-retinol derivatives Chemical class 0.000 claims 1
- 125000001153 fluoro group Chemical class F* 0.000 claims 1
- 229960002449 glycine Drugs 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- 150000007513 acids Chemical class 0.000 description 10
- 239000013078 crystal Substances 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 229910052757 nitrogen Inorganic materials 0.000 description 9
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- UGEPSJNLORCRBO-UHFFFAOYSA-N [3-(dimethylamino)-1-hydroxy-1-phosphonopropyl]phosphonic acid Chemical compound CN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O UGEPSJNLORCRBO-UHFFFAOYSA-N 0.000 description 8
- 229940046231 pamidronate Drugs 0.000 description 8
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 7
- 229940009626 etidronate Drugs 0.000 description 7
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical group [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-BKFZFHPZSA-N Calcium-45 Chemical compound [45Ca] OYPRJOBELJOOCE-BKFZFHPZSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 239000011575 calcium Substances 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- ABLZXFCXXLZCGV-UHFFFAOYSA-N phosphonic acid group Chemical group P(O)(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 230000002950 deficient Effects 0.000 description 3
- 230000001605 fetal effect Effects 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000006386 Bone Resorption Diseases 0.000 description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000004097 bone metabolism Effects 0.000 description 2
- 230000024279 bone resorption Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 238000000921 elemental analysis Methods 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052744 lithium Inorganic materials 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000030991 negative regulation of bone resorption Effects 0.000 description 2
- 230000002188 osteogenic effect Effects 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- ISIJQEHRDSCQIU-UHFFFAOYSA-N tert-butyl 2,7-diazaspiro[4.5]decane-7-carboxylate Chemical compound C1N(C(=O)OC(C)(C)C)CCCC11CNCC1 ISIJQEHRDSCQIU-UHFFFAOYSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- AILDTIZEPVHXBF-UHFFFAOYSA-N Argentine Natural products C1C(C2)C3=CC=CC(=O)N3CC1CN2C(=O)N1CC(C=2N(C(=O)C=CC=2)C2)CC2C1 AILDTIZEPVHXBF-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 244000308495 Potentilla anserina Species 0.000 description 1
- 235000016594 Potentilla anserina Nutrition 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- AGSPXMVUFBBBMO-UHFFFAOYSA-N beta-aminopropionitrile Chemical compound NCCC#N AGSPXMVUFBBBMO-UHFFFAOYSA-N 0.000 description 1
- 230000003913 calcium metabolism Effects 0.000 description 1
- QXDMQSPYEZFLGF-UHFFFAOYSA-L calcium oxalate Chemical compound [Ca+2].[O-]C(=O)C([O-])=O QXDMQSPYEZFLGF-UHFFFAOYSA-L 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 230000001085 cytostatic effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 150000002634 lipophilic molecules Chemical class 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003009 phosphonic acids Chemical class 0.000 description 1
- IPNPIHIZVLFAFP-UHFFFAOYSA-N phosphorus tribromide Chemical compound BrP(Br)Br IPNPIHIZVLFAFP-UHFFFAOYSA-N 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000004575 stone Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-N sulfonic acid Chemical compound OS(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/16—Fluorine compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3839—Polyphosphonic acids
- C07F9/3873—Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.以下の構造式の、1−アミノ−3−(N,N−ジメチルアミノ)−プロピリ デン−1,1−ビスホスホン酸: またはその一ナトリウム塩またはその他の薬学的に許容可能な塩の、他の骨活性 物質の生物学的キャリアとしての利用。 2.前記他の骨活性物質が、サイトカイン、増殖因子、プロスタグランジン、ホ ルモン、グリシンまたは他のアミノ酸または修飾アミノ酸、および細胞増殖抑制 性薬剤から成る群より選択されることを特徴とする請求の範囲第1項記載の利用 。 3.以下の構造式の、1−アミノ−3−(N,N−ジメチルアミノ)−プロピリ デン−1,1−ビスホスホン酸: またはその一ナトリウム塩またはその他の薬学的に許容可能な塩の、骨および/ または鉱物代謝異常の診断、予防および/または治療用の薬剤の調製のための利 用。 4.尿石症、異所性石灰化、全ての型の骨粗しょう症、全ての型の関節炎、全て の型の歯周病の診断、予防および/または治療用の薬剤の調製のためであること を特徴とする請求の範囲第3項記載の利用。 5.少なくとも1つのカルシウム塩の同時または連続的な投与を含むことを特徴 とする請求の範囲第1−4項何れか1項記載の利用。 6.ビタミンDまたはそれらの派生体の、同時または連続的な投与を含むことを 特徴とする請求の範囲第1−5項何れか1項記載の利用。 7.少なくとも1つのフッ素塩の同時または連続的な投与を含むことを特徴とす る前出の請求の範囲何れか1項記載の利用。 8.少なくとも1つの副甲状腺ホルモンの同時または連続的な投与を含むことを 特徴とする前出の請求の範囲何れか1項記載の利用。 9.少なくとも1つのアンドロゲンの同時または連続的な投与を含むことを特徴 とする前出の請求の範囲何れか1項記載の利用。 10.少なくとも1つのエストロゲンの同時または連続的な投与を含むことを特徴 とする前出の請求の範囲何れか1項記載の利用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP95110706.9 | 1995-07-10 | ||
EP95110706A EP0753523A1 (en) | 1995-07-10 | 1995-07-10 | Amino-substituted bisphosphonic acids |
PCT/EP1996/002981 WO1997002827A1 (en) | 1995-07-10 | 1996-07-08 | Therapeutic use of 1-amino-3-(n,n-dimethylamino)-propyliden-1,1-bisphosphonic acid and its salts |
Publications (1)
Publication Number | Publication Date |
---|---|
JPH11508905A true JPH11508905A (ja) | 1999-08-03 |
Family
ID=8219423
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP9505494A Ceased JPH11508905A (ja) | 1995-07-10 | 1996-07-08 | アミノ置換ビスホスホン酸 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5990098A (ja) |
EP (2) | EP0753523A1 (ja) |
JP (1) | JPH11508905A (ja) |
AR (1) | AR004625A1 (ja) |
AU (1) | AU6612596A (ja) |
DE (1) | DE69624707T2 (ja) |
WO (1) | WO1997002827A1 (ja) |
ZA (1) | ZA965798B (ja) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6660468B1 (en) | 1998-10-27 | 2003-12-09 | Board Of Trustees Of The University Of Arkansas | Vitro and in vivo models for screening compounds to prevent glucocorticoid-induced bone destruction |
AR013994A1 (es) * | 1998-10-30 | 2001-01-31 | Gador Sa | Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes. |
AU1525700A (en) | 1998-11-19 | 2000-06-05 | Board Of Trustees Of The University Of Arkansas, The | Increasing bone strength with selected bisphosphonates |
AU2003234670B2 (en) | 2002-05-24 | 2010-06-10 | Angiotech International Ag | Compositions and methods for coating medical implants |
JP4463274B2 (ja) * | 2003-06-27 | 2010-05-19 | 明 小谷 | ビスホスホネート錯体 |
WO2005090370A1 (en) | 2004-02-05 | 2005-09-29 | The Regents Of The University Of California | Pharmacologically active agents containing esterified phosphonates and methods for use thereof |
EP1758594A1 (en) * | 2004-05-19 | 2007-03-07 | Merck and Co., Inc. | Combination for inhibiting bone resorption comprising a bisphosponate (alendrona) and a vitamin d (cholecalciferol) |
US7068172B2 (en) * | 2004-05-21 | 2006-06-27 | Xiao Hui Yang | Method and apparatus for deactivating an EAS device |
EP2842559A3 (en) | 2005-04-08 | 2015-03-18 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of viral infections and other medical disorders |
EP1868628B1 (en) | 2005-04-08 | 2014-06-11 | Chimerix, Inc. | Compounds, compositions and methods for the treatment of poxvirus infections |
EP2254582B1 (en) | 2008-01-25 | 2016-01-20 | Chimerix, Inc. | Methods of treating viral infections |
WO2011011519A1 (en) | 2009-07-21 | 2011-01-27 | Chimerix, Inc. | Compounds, compositions and methods for treating ocular conditions |
EP2462152A4 (en) | 2009-08-03 | 2013-02-13 | Chimerix Inc | COMPOSITION AND METHODS FOR TREATING VIRAL INFECTIONS AND TUMORS OF VIRAL ORIGIN |
US9006218B2 (en) | 2010-02-12 | 2015-04-14 | Chimerix Inc. | Nucleoside phosphonate salts |
EP2563367A4 (en) | 2010-04-26 | 2013-12-04 | Chimerix Inc | METHODS OF TREATING RETROVIRAL INFECTIONS AND ASSOCIATED DOSAGE REGIMES |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1002355C2 (de) * | 1954-05-03 | 1957-07-25 | Thomae Gmbh Dr K | Verfahren zur Herstellung von ª‡-prim.-Amino-diphosphonsaeuren und deren Estern |
FR8441M (ja) * | 1968-04-01 | 1971-07-15 | ||
DE2405254C2 (de) | 1974-02-04 | 1982-05-27 | Henkel KGaA, 4000 Düsseldorf | Verwendung von 3-Amino-1-Hydroxypropan-1, 1-diphosphonsäure oder ihrer wasserlöslichen Salze bei der Beeinflußung von Calciumstoffwechselstörungen im menschlichen oder tierischen Körper |
AR200473A1 (es) | 1974-09-17 | 1974-11-08 | Gador Y Cia Sa Com E Ind Lab | Procedimiento para preparar acidos 1-hidroxialquiliden-difosfonicos y sus sales |
GB1508772A (en) * | 1975-04-04 | 1978-04-26 | Shell Int Research | Biologically active compositions |
DE2534390C2 (de) * | 1975-08-01 | 1983-01-13 | Henkel KGaA, 4000 Düsseldorf | 1,3-Di-aminoalkan-1,1-diphosphonsäuren |
DE2534391C2 (de) | 1975-08-01 | 1983-01-13 | Henkel KGaA, 4000 Düsseldorf | 1-Hydroxy-3-aminoalkan-1,1-diphosphonsäuren |
AR218558A1 (es) | 1979-09-28 | 1980-06-13 | Gador Lab & Cia Sa | Procedimiento para preparar acido 3-amino-1-hidroxi-propilidendifosfonico y sus sales |
US4822609A (en) * | 1984-12-21 | 1989-04-18 | The Procter & Gamble Company | Treatment of osteoporosis |
DE3623397A1 (de) | 1986-07-11 | 1988-01-14 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US4868164A (en) | 1986-12-19 | 1989-09-19 | Norwich Eaton Pharmaceuticals, Inc. | Octahydro-pyridine diphosphonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
US5006329A (en) | 1988-01-22 | 1991-04-09 | Cadema Medical Products, Inc. | Radioactive tagged compounds and method for the treatment of metastatic bone cancer |
DE3917153A1 (de) | 1989-05-26 | 1990-11-29 | Boehringer Mannheim Gmbh | Neue diphosphonsaeurederivate, verfahren zu deren herstellung und diese verbindungen enthaltende arzneimittel |
US5039819A (en) | 1990-09-18 | 1991-08-13 | Merck & Co., Inc. | Diphosphonate intermediate for preparing an antihypercalcemic agent |
US5103036A (en) | 1991-05-13 | 1992-04-07 | E. R. Squibb & Sons, Inc. | Process for preparing 3-alkenylidene-1,1-bisphosphonates |
EP0541037A3 (en) | 1991-11-06 | 1997-02-26 | Takeda Chemical Industries Ltd | Squalene synthetase inhibitory composition and use thereof |
US5205253A (en) | 1992-08-24 | 1993-04-27 | Ford Motor Company | Engine operation interrupt using engine operating parameters |
FR2703590B1 (fr) * | 1993-04-05 | 1995-06-30 | Sanofi Elf | Utilisation de derives d'acide bisphosphonique pour la preparation de medicaments destines a favoriser la reparation osseuse . |
JPH09511927A (ja) * | 1994-04-18 | 1997-12-02 | ザ、プロクター、エンド、ギャンブル、カンパニー | 歯槽骨へのビスホスホネート類のイオン導入デリバリー |
KR100385697B1 (ko) * | 1994-12-28 | 2003-08-21 | 가도르 에스. 에이. | 올파드로네이트를포함하는골체량동화성조성물 |
-
1995
- 1995-07-10 EP EP95110706A patent/EP0753523A1/en not_active Withdrawn
-
1996
- 1996-07-08 AU AU66125/96A patent/AU6612596A/en not_active Abandoned
- 1996-07-08 EP EP96925679A patent/EP0837682B1/en not_active Expired - Lifetime
- 1996-07-08 AR ARP960103486A patent/AR004625A1/es not_active Application Discontinuation
- 1996-07-08 WO PCT/EP1996/002981 patent/WO1997002827A1/en active IP Right Grant
- 1996-07-08 JP JP9505494A patent/JPH11508905A/ja not_active Ceased
- 1996-07-08 US US08/983,247 patent/US5990098A/en not_active Expired - Lifetime
- 1996-07-08 DE DE69624707T patent/DE69624707T2/de not_active Expired - Lifetime
- 1996-07-09 ZA ZA9605798A patent/ZA965798B/xx unknown
Also Published As
Publication number | Publication date |
---|---|
DE69624707D1 (de) | 2002-12-12 |
DE69624707T2 (de) | 2003-03-20 |
US5990098A (en) | 1999-11-23 |
EP0837682A1 (en) | 1998-04-29 |
EP0753523A1 (en) | 1997-01-15 |
EP0837682B1 (en) | 2002-11-06 |
AR004625A1 (es) | 1999-03-10 |
WO1997002827A1 (en) | 1997-01-30 |
AU6612596A (en) | 1997-02-10 |
ZA965798B (en) | 1998-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JPH11508905A (ja) | アミノ置換ビスホスホン酸 | |
KR101813728B1 (ko) | 결정화 방법 및 생체이용률 | |
JP2516599B2 (ja) | Nmr走査用コントラスト剤 | |
HUP0203078A2 (hu) | Az allendronát-nátrium új hidrátformái, eljárás azok előállítására és ilyen vegyületeket tartalmazó gyógyászati készítmények | |
JPS58189193A (ja) | 薬理活性を有するバイホスホネートを有効成分とする医薬 | |
HUP0204114A2 (hu) | Bifoszfonáttartalmú parenterális gyógyászati készítmény | |
HUP0000383A2 (hu) | Tetrahidro-kinoxalinil-(amino-alkil)-foszfonsavak, eljárás előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
Joseph et al. | Inhibition of growth of urinary type calcium hydrogen phosphate dihydrate crystals by tartaric acid and tamarind | |
EP1723157B2 (en) | Amorphous forms of risedronate monosodium | |
Yewle et al. | Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone | |
EP1556041B1 (en) | New crystalline hydrates of the sodium salt of 3-pyridyl-1-hydroxyethylidene-1,1-bisphosphonic acid | |
Li et al. | Effect of lanthanide ions on the phase behavior of dipalmitoylphosphatidylcholine multilamellar liposomes | |
EP0994884B1 (en) | Diphosphonic acid salts for the treatment of osteoporosis | |
JP3883137B2 (ja) | ピリジルビスホスホン酸エステルよりなる治療用活性薬剤 | |
CZ20011820A3 (cs) | Fosfororganické sloučeniny a jejich použití | |
EA008494B1 (ru) | Кристаллическая форма мононатрия ризедроната | |
Alanne | Novel applications related to bisphosphorus compounds | |
CS269719B1 (en) | Platinum cytostatic | |
JP2001520232A (ja) | 新規なメチレンビスホスホン酸誘導体 | |
EP0891979B1 (en) | A crystalline form of monohydrate monosodium salt of the N,N-Dimethyl-3-amino-1-Hydroxypropan-1,1-Disphosphonic acid and the procedure for its preparation | |
Carmona et al. | Hydrogen bonds between protein side chains and phosphates and their role in biological calcification | |
Eanes | Physico-chemical principles of biomineralization | |
JPH04112832A (ja) | 抗腫瘍剤 | |
JP2002332235A (ja) | 骨疾患治療用液体医薬組成物 | |
JP2003508537A (ja) | リン含有エチレンジアミン誘導体のカルシウム錯体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040315 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040426 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040427 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060919 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20061212 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070117 |
|
A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070129 |
|
A911 | Transfer of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070215 |
|
A912 | Removal of reconsideration by examiner before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20070222 |
|
A313 | Final decision of rejection without a dissenting response from the applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A313 Effective date: 20070502 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070612 |